Multidisciplinary follow-up clinic findings in COVID-19
| Symptom | Number affected |
|---|---|
| Fatigue | 36 (97%) |
| Persistent functional status decline | 29 (78%) |
| Mental health complications including post-traumatic stress disorder | 29 (78%) |
| Breathlessness; pulmonary complications including dysfunctional breathing / venous thromboembolic disease / persistent pulmonary infiltrates | 28 (76%) |
| Telogen effluvium | 27 (73%) |
| Ongoing memory impairment / concentration issues | 25 (68%) |
| Neuropathic pain / brachial plexus injury / brain injury | 21 (57%) |
| Sleep disturbance | 14 (38%) |
| Renal dysfunction (AKI 1–3) with ongoing surveillance requirement | 20 (54%) |
| Social issues | 7 (18%) |
| Visual concerns | 6 (16%) |
| Dry mouth | 2 (5%) |
| Persistent anosmia | 2 (5%) |